Trials / Conditions / Papillary Renal Cell Carcinoma

Papillary Renal Cell Carcinoma

21 registered clinical trials studyying Papillary Renal Cell Carcinoma — 6 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Tumor-Derived Extracellular Vesicles for Noninvasive Molecular Classification of Kidney Cancer NCT07243067	Mayo Clinic	—
Recruiting	Real World Study of Effectiveness of Sunitinib or Sorafenib to Chinese Unresectable Locally Advanced or Metast NCT07024680	AstraZeneca	—
Not Yet Recruiting	Multi-classifier System for Stratifying Stage III Papillary Renal Cell Carcinoma of Receiving Adjuvant Therapy NCT06146777	First Affiliated Hospital, Sun Yat-Sen University	Phase 3
Active Not Recruiting	Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer NCT05620134	Salubris Biotherapeutics Inc	Phase 1 / Phase 2
Recruiting	Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer NCT04981509	National Cancer Institute (NCI)	Phase 2
Active Not Recruiting	Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locall NCT05043090	AstraZeneca	Phase 3
Withdrawn	Pamiparib and Temozolomide for the Treatment of Hereditary Leiomyomatosis and Renal Cell Cancer NCT04603365	Jonsson Comprehensive Cancer Center	Phase 2
Active Not Recruiting	Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC NCT04413123	Bradley A. McGregor, MD	Phase 2
Active Not Recruiting	Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) f NCT04071223	National Cancer Institute (NCI)	Phase 2
Recruiting	An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Bi NCT04623502	University of Texas Southwestern Medical Center	N/A
Recruiting	Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted NCT03866382	National Cancer Institute (NCI)	Phase 2
Active Not Recruiting	A Study of Nivolumab In Combination With Cabozantinib in Patients With Non-Clear Cell Renal Cell Carcinoma NCT03635892	Memorial Sloan Kettering Cancer Center	Phase 2
Active Not Recruiting	Identification of Novel High Quality Methylated DNA Markers in Renal Tumors: Whole Methylome Discovery, Tissue NCT06339138	Mayo Clinic	—
Active Not Recruiting	Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcino NCT03541902	M.D. Anderson Cancer Center	Phase 2
Terminated	A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and Ovarian Clea NCT02837991	Celldex Therapeutics	Phase 1
Completed	Axitinib in1st Line Treatment for Patients With Advanced or Metastatic Papillary Renal Cell Carcinoma NCT02489695	Centre Leon Berard	Phase 2
Completed	Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer NCT01767636	Mayo Clinic	Phase 2
Completed	Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors NCT00335556	Children's Oncology Group	Phase 2
Active Not Recruiting	Study of Kidney Tumors in Younger Patients NCT00898365	Children's Oncology Group	—
Completed	Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer NCT00126503	National Cancer Institute (NCI)	Phase 1 / Phase 2
Terminated	Sorafenib and Interferon Alfa in Treating Patients With Locally Advanced or Metastatic Kidney Cancer NCT00098618	National Cancer Institute (NCI)	Phase 2